Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
Masera
N
N
Pediatric Department, University of Milano-Bicocca, San Gerardo Hospital, via Pergolesi 33, 20052 Monza, Italy. nicoletta.masera@pediatriamonza.it
Rescaldani
C
C
Azzolini
M
M
Vimercati
C
C
Tavecchia
L
L
Masera
G
G
De Molfetta
V
V
Arpa
P
P
D000293:Adolescent; D000328:Adult; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D002386:Cataract / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007558:Italy; D013997:Time Factors; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox